Sci Rep: New study reveals combination therapy for COVID-19.

8, 2020 /---Xinface, Scientific Reports, the results of this new study support the use of fda-approved hepatitis C drug EPCLUSA (Sofosbuvir / Velpatasvir) in COVID-19 clinical trials along with other drugs.
the ability to proofread SARS-CoV-2 nucleic acid exoceps to maintain the accuracy of viral RNA genome replication to maintain its toxicity.
, any effective antiviral drug against SARS-CoV-2 polymerases must exhibit a degree of resistance to this proofreading activity.
"We found that RNA targeted by Soofosbuvir is much more resistant to exonysistase than Remdesivir," said SAMUEL Ruben-Peter G, head of the research team at www.pixabay.com.
" new study builds on previous work done by researchers.
January last year, before COVID-19 reached a pandemic, the team thought EPCLUSA might inhibit replication of the SARS-CoV-2 virus.
their reasoning is based on an analysis of the molecular structure and activity of hepatitis C virus inhibitors and a comparison of hepatitis C virus and coronavirus replication.
a subsequent study, researchers demonstrated that Sofosbuvir inhibits the activity of SARS-CoV and SARS-CoV-2 polymerases, thereby blocking polymerase reactions.
, other researchers have demonstrated Sofosbuvir's ability to inhibit SARS-CoV-2 replication in lung and brain cells.
currently, COVID-19 clinical trials using hepatitis C drugs such as EPCLUSA and a combination of Sofosbuvir and Daclatasvir have been conducted in several countries.
(bioon.com) Source: New research supports sofosbuvir in the same with other antivirals for COVID-19 Original source: Steffen Jockusch et al, Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir, Scientific Reports (2020). DOI: 10.1038/s41598-020-73641-9.